Search

everythinglearnresearchcommunity

for

Search:↓

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

64 drugs can cause hair loss, needing better monitoring and updated labels.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Ixekizumab has known and some unexpected side effects.

Fesoterodine is effective and safe for elderly patients with overactive bladder.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Efalizumab can cause unexpected excessive hair growth.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Adalimumab improved folliculitis decalvans in most patients.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.